Neural Cell News

Neural Cell News is an online resource covering the latest research in neuroscience, neural stem cells, and neurological conditions.

Inhibition of PERK Mediated UPR Acts as a Switch for Reversal of Residual Senescence and as Senolytic Therapy in Glioblastoma

[Neuro-Oncology] Researchers delineated therapy induced senescence reversal mechanisms for potential therapeutic intervention to prevent glioblastoma recurrence.

First Patient Dosed in Phase III Gliofocus Study for Newly Diagnosed Glioblastoma Patients at the Ivy Brain Tumor Center

[Ivy Brain Tumor Center] The Ivy Brain Tumor Center at Barrow Neurological Institute announced that the first patient has been dosed in the Phase III Gliofocus Study. Gliofocus is an open-label, randomized Phase III trial that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.

Cellular and Pathological Functions of Tau

[Nature Reviews Molecular Cell Biology] The authors review recent insights into the diverse cellular functions of tau and the pathology of tau inclusions and explore the potential for therapeutic interventions.

Multiscale Modeling Uncovers 7q11.23 Copy Number Variation–Dependent Changes in Ribosomal Biogenesis and Neuronal Maturation and Excitability

[Journal of Clinical Investigation] By integrating transcriptomics, translatomics, and proteomics of patient-derived and isogenic induced neurons, researchers reported that genes related to neuronal transmission followed 7q11.23 dosage and were transcriptionally controlled, while translational factors and ribosomal genes were posttranscriptionally buffered.

De Novo Monoallelic Reelin Missense Variants Act in a Dominant-Negative Manner Causing Neuronal Migration Disorders

[Journal of Clinical Investigation] Researchers identified inherited and de novo Reelin (RELN) missense variants in heterozygous patients with neuronal migration disorders as diverse as pachygyria and polymicrogyria. They investigated in culture and in the developing mouse cerebral cortex how different variants impacted RELN function.

CryoET of β-Amyloid and Tau within Postmortem Alzheimer’s Disease Brain

[Nature] Using cryo-fluorescence microscopy-targeted cryo-sectioning, cryo-focused ion beam-scanning electron microscopy lift-out and cryo-electron tomography, the authors determined in-tissue architectures of β-amyloid and tau pathology in a postmortem Alzheimer’s disease donor brain.

β-Amyloid Monomer Scavenging by an Anticalin Protein Prevents Neuronal Hyperactivity in Mouse Models of Alzheimer’s Disease

[Nature Communications] Using in vivo two-photon calcium imaging and SF-iGluSnFR-based glutamate imaging in hippocampal slices, investigators demonstrate that an Aβ binding anticalin protein could suppress early neuronal hyperactivity and synaptic glutamate accumulation in a mouse model of β-amyloidosis.

LRIG1 Controls Proliferation of Adult Neural Stem Cells by Facilitating TGFβ and BMP Signaling Pathways

[Communications Biology] Investigators characterized the mechanism underlying the functional role of a cell-signaling inhibitory protein, leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1), in the control of adult neural stem cell proliferation.

Preclinical and Clinical Advances to Overcome Hypoxia in Glioblastoma Multiforme

[Cell Death & Disease] The authors discuss the recent preclinical and clinical approaches that aim at targeting tumor hypoxia to enhance the response of glioblastoma multiforme to conventional therapies along with their results and limitations upon clinical translation.

AskBio Receives FDA Fast Track and MHRA Innovation Passport Designations for AB-1005 Investigational GDNF Gene Therapy for Parkinson’s Disease

[Asklepios BioPharmaceutical, Inc.] Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio) announced that the US FDA has granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency innovative medicine designation, for the treatment of Parkinson’s disease.

Monoallelic De Novo AJAP1 Loss-of-Function Variants Disrupt Trans-synaptic Control of Neurotransmitter Release

[Science Advances] Scientists showed that adherens junction–associated protein 1 (AJAP1) was selectively expressed in dendrites and trans-synaptically recruits γ-aminobutyric acid type B receptors to presynaptic sites of neurons expressing AJAP1.

Connexin 30 Locally Controls Actin Cytoskeleton and Mechanical Remodeling in Motile Astrocytes

[Glia] Researchers found in vitro that connexin 30 interacted with the actin cytoskeleton in astrocytes and inhibited its structural reorganization and dynamics during cell migration.

Neural Cell News helps scientists keep pace with the latest research, reviews, and industry developments in neuroscience. Specific research topics include neural development and neuroregeneration, neural signaling related to cellular responses and behavior, and synaptic plasticity. Research into the diagnosis, progression, cellular characteristics, and treatment of brain diseases such as Parkinson’s, Multiple Sclerosis, Alzheimer’s, Amyotrophic Lateral Sclerosis and various brain cancers, as well as brain damage resulting from infection, trauma, stroke, seizures, and tumors, is also covered.